196 related articles for article (PubMed ID: 8677619)
1. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
Valladares JE; Alberola J; Esteban M; Arboix M
Vet Rec; 1996 Feb; 138(8):181-3. PubMed ID: 8677619
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog.
Tassi P; Ormas P; Madonna M; Carli S; Belloli C; De Natale G; Ceci L; Marcotrigiano GO
Res Vet Sci; 1994 Mar; 56(2):144-50. PubMed ID: 8191002
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M
Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs.
Valladares JE; Freixas J; Alberola J; Franquelo C; Cristofol C; Arboix M
Am J Trop Med Hyg; 1997 Oct; 57(4):403-6. PubMed ID: 9347953
[TBL] [Abstract][Full Text] [Related]
5. Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs.
Belloli C; Crescenzo G; Carli S; Zaghini A; Mengozzi G; Bertini S; Ormas P
Vet J; 1999 May; 157(3):315-21. PubMed ID: 10328843
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Braz J Med Biol Res; 2005 Dec; 38(12):1879-83. PubMed ID: 16302103
[TBL] [Abstract][Full Text] [Related]
7. Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis.
Belloli C; Ceci L; Carli S; Tassi P; Montesissa C; De Natale G; Marcotrigiano G; Ormas P
Res Vet Sci; 1995 Mar; 58(2):123-7. PubMed ID: 7761689
[TBL] [Abstract][Full Text] [Related]
8. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ
J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235
[TBL] [Abstract][Full Text] [Related]
9. Distribution of liposome-encapsulated antimony in dogs.
Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Braz J Med Biol Res; 2003 Feb; 36(2):269-72. PubMed ID: 12563530
[TBL] [Abstract][Full Text] [Related]
10. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
Amusategui I; Sainz A; Tesouro MA
Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
Chulay JD; Fleckenstein L; Smith DH
Trans R Soc Trop Med Hyg; 1988; 82(1):69-72. PubMed ID: 2845611
[TBL] [Abstract][Full Text] [Related]
12. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
Gramiccia M; Gradoni L; Orsini S
Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
[TBL] [Abstract][Full Text] [Related]
13. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis.
Amusategui I; Sainz A; Tesouro MA
Ann N Y Acad Sci; 1998 Jun; 849():447-9. PubMed ID: 9668510
[No Abstract] [Full Text] [Related]
14. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis.
Miekeley N; Mortari SR; Schubach AO
Anal Bioanal Chem; 2002 Feb; 372(3):495-502. PubMed ID: 11939540
[TBL] [Abstract][Full Text] [Related]
16. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial.
Slappendel RJ; Teske E
Vet Q; 1997 Mar; 19(1):10-3. PubMed ID: 9225422
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
Carrió J; Portús M
BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
[TBL] [Abstract][Full Text] [Related]
18. Antimony determination in tissues and serum of hamsters infected with Leishmania garnhami and treated with meglumine antimoniate.
Lugo de Yarbuh A; Añez N; Petit de Peña Y; Burguera JL; Burguera M
Ann Trop Med Parasitol; 1994 Feb; 88(1):37-41. PubMed ID: 8192513
[TBL] [Abstract][Full Text] [Related]
19. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment.
Gradoni L; Maroli M; Gramiccia M; Mancianti F
Med Vet Entomol; 1987 Oct; 1(4):339-42. PubMed ID: 2979550
[TBL] [Abstract][Full Text] [Related]
20. Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.
Gómez Pérez V; García-Hernandez R; Corpas-López V; Tomás AM; Martín-Sanchez J; Castanys S; Gamarro F
Int J Parasitol Drugs Drug Resist; 2016 Aug; 6(2):133-9. PubMed ID: 27317865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]